HC Wainwright & Co. Reiterates Buy on scPharmaceuticals, Maintains $18 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on scPharmaceuticals (NASDAQ:SCPH) and maintained a price target of $18.
August 11, 2023 | 12:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
scPharmaceuticals (NASDAQ:SCPH) has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $18.
The reiteration of a 'Buy' rating by a reputable analyst like Douglas Tsao from HC Wainwright & Co. is a positive signal for scPharmaceuticals. The maintained price target of $18 indicates the analyst's confidence in the company's potential to reach this value. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100